口服大环肽MK-0616抑制PCSK9与LDL受体结合
研究利用mRNA展示技术筛选并优化出大环肽MK-0616,体外对PCSK9亲和力Ki=5pM。健康成人单次口服后游离PCSK9几何均值降低>93%(95%CI 84-103);他汀治疗者每日20mg×14天使LDL-C几何均值最大降低61%(95%CI 43-85)。
要点
- 口服MK-0616单次给药可使游离PCSK9几何均值降低>93%。
- 他汀治疗者每日20mg×14天,LDL-C几何均值最大降低61%。
- MK-0616为口服PCSK9抑制剂,兼具高亲和力与口服生物利用度。
核心结论
- 本研究验证mRNA展示技术可发现新型口服治疗药物,MK-0616作为口服PCSK9抑制剂有望成为高效降胆固醇疗法。
研究设计与样本
- 采用新型mRNA展示技术筛选先导化合物,经结构导向药物设计优化得到大环肽MK-0616。
- 完成非临床安全性研究后,在健康成人中开展单次递增剂量1期临床试验评估安全性、药代动力学和药效学。
- 在服用他汀的受试者中开展多次给药试验,每日一次给药14天,评估安全性、药代动力学和LDL-C变化。
主要发现
- MK-0616在体外对PCSK9显示高亲和力,Ki=5pM。
- 健康成人单次口服MK-0616后,游离未结合血浆PCSK9几何均值降低>93%(95%CI 84-103)。
- 他汀治疗者每日一次20mg MK-0616治疗14天后,LDL-C较基线几何均值最大降低61%(95%CI 43-85)。
临床怎么用
- MK-0616作为口服PCSK9抑制剂,可能为需要降胆固醇治疗的患者提供高效口服选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2 decades of effort, an oral inhibitor of PCSK9 is not available. Macrocyclic peptides represent a novel approach to target proteins traditionally considered intractable to small-molecule drug design. METHODS: Novel mRNA display screening technology was used to identify lead chemical matter, which was then optimized by applying structure-based drug design enabled by novel synthetic chemistry to identify macrocyclic peptide (MK-0616) with exquisite potency and selectivity for PCSK9. Following completion of nonclinical safety studies, MK-0616 was administered to healthy adult participants in a single rising-dose Phase 1 clinical trial designed to evaluate its safety, pharmacokinetics, and pharmacodynamics. In a multiple-dose trial in participants taking statins, MK-0616 was administered once daily for 14 days to characterize the safety, pharmacokinetics, and pharmacodynamics (change in low density lipoprotein cholesterol). RESULTS: MK-0616 displayed high affinity (Ki = 5pM) for PCSK9 in vitro and sufficient safety and oral bioavailability preclinically to enable advancement into the clinic. In Phase 1 clinical studies in healthy adults, single oral doses of MK-0616 were associated with >93% geometric mean reduction (95% CI, 84-103) of free, unbound plasma PCSK9; in participants on statin therapy, multiple-oral-dose regimens provided a maximum 61% geometric mean reduction (95% CI, 43-85) in low density lipoprotein cholesterol from baseline after 14 days of once-daily dosing of 20 mg MK-0616. CONCLUSIONS: This work validates the use of mRNA display technology for identification of novel oral therapeutic agents, exemplified by the identification of an oral PCSK9 inhibitor, which has the potential to be a highly effective cholesterol lowering therapy for patients in need.
引用
- Johns DG, Campeau LC, Banka P, et al. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation. 2023. PMID: 37125593. doi:10.1161/CIRCULATIONAHA.122.063372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。